MannKind Corp Cash Flow Conversion Efficiency
MannKind Corp cash flow conversion efficiency. Based on the latest financial reports, MannKind Corp (MNKD) has a cash flow conversion efficiency ratio of 0.273x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.37 Million) by net assets ($-67.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MannKind Corp (2002–2025)
Cash flow conversion efficiency of MannKind Corp from 2002 to 2025. This chart illustrates how MannKind Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MannKind Corp stock quote for real-time trading data and today's change.
MannKind Corp Cash Flow Conversion Ratio Explained
MannKind Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MannKind Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MannKind Corp ranked by their cash flow conversion efficiency. Also see MannKind Corp market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aker Biomarine AS
OL:AKBM
|
-0.046x |
|
TMC the metals company Inc
NASDAQ:TMC
|
0.340x |
|
UTI Asset Management Company Limited
NSE:UTIAMC
|
0.005x |
|
Shenzhen Jufei Optoelectronics
SHE:300303
|
0.002x |
|
Certara Inc
NASDAQ:CERT
|
0.027x |
|
Cymbria Corporation
TO:CYB
|
0.001x |
|
PROS Holdings Inc
NYSE:PRO
|
-0.149x |
|
Hagar hf
IC:HAGA
|
0.078x |
Annual Cash Flow Conversion Efficiency for MannKind Corp (2002–2025)
The table below shows the annual cash flow conversion efficiency of MannKind Corp from 2002 to 2025. Review MannKind Corp free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-51.02 Million | $18.25 Million | -0.358x | +33.67% |
| 2024-12-31 | $-78.82 Million | $42.51 Million | -0.539x | -289.44% |
| 2023-12-31 | $-246.17 Million | $34.09 Million | -0.138x | -143.00% |
| 2022-12-31 | $-250.54 Million | $-80.70 Million | 0.322x | +9.27% |
| 2021-12-31 | $-209.35 Million | $-61.71 Million | 0.295x | +89.07% |
| 2020-12-31 | $-180.42 Million | $-28.13 Million | 0.156x | -66.43% |
| 2019-12-31 | $-190.53 Million | $-88.48 Million | 0.464x | +115.50% |
| 2018-12-31 | $-175.08 Million | $-37.73 Million | 0.216x | -28.56% |
| 2017-12-31 | $-214.73 Million | $-64.78 Million | 0.302x | -29.08% |
| 2016-12-31 | $-183.59 Million | $-78.09 Million | 0.425x | +160.37% |
| 2015-12-31 | $-350.33 Million | $-57.23 Million | 0.163x | +394.94% |
| 2014-12-31 | $-73.77 Million | $4.09 Million | -0.055x | -101.32% |
| 2013-12-31 | $-30.71 Million | $-128.73 Million | 4.191x | +287.04% |
| 2012-12-31 | $-110.68 Million | $-119.86 Million | 1.083x | +174.29% |
| 2011-12-31 | $-313.65 Million | $-123.84 Million | 0.395x | -50.72% |
| 2010-12-31 | $-185.53 Million | $-148.65 Million | 0.801x | -74.22% |
| 2009-12-31 | $-59.22 Million | $-184.08 Million | 3.108x | +199.38% |
| 2008-12-31 | $86.73 Million | $-271.29 Million | -3.128x | -364.55% |
| 2007-12-31 | $364.10 Million | $-245.15 Million | -0.673x | -36.04% |
| 2006-12-31 | $383.49 Million | $-189.79 Million | -0.495x | -1.19% |
| 2005-12-31 | $206.98 Million | $-101.23 Million | -0.489x | -22.75% |
| 2004-12-31 | $150.36 Million | $-59.91 Million | -0.398x | +15.75% |
| 2003-12-31 | $111.58 Million | $-52.77 Million | -0.473x | +11.78% |
| 2002-12-31 | $90.77 Million | $-48.67 Million | -0.536x | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more